Bloodstream Infection Testing Market Trends, Growth Drivers, CAGR Status, Revenue and Future Outlook
Bloodstream Infection Testing Market Growth, Size, Trends Analysis - By Product, By Sample Type, By Technology, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Mar-2025 | Report ID: HLCA2596 | Pages: 1 - 263 | Formats*: |
| Category : Healthcare | |||
Bloodstream Infection Testing Market Introduction and Overview
According to SPER Market Research, the Global Bloodstream Infection Testing Market is estimated to reach USD 1208.2 million by 2034 with a CAGR of 4.59%.
The report includes an in-depth analysis of the Global Bloodstream Infection Testing Market, including market size and trends, Interface mix, Applications, and supplier analysis.
Bloodstream infection (BSI) testing is a critical diagnostic process used to detect bacterial, fungal, or viral pathogens in the blood, enabling timely treatment and reducing the risk of severe complications such as sepsis. The market for BSI testing is growing due to the rising incidence of hospital-acquired infections, increasing antibiotic resistance, and a growing elderly population prone to infections. Technological advancements, such as rapid molecular diagnostics and automated blood culture systems, are improving detection speed and accuracy. However, challenges such as the high cost of advanced testing methods, limited access to diagnostic facilities in low-income regions, and the complexity of differentiating contaminants from true infections hinder widespread adoption. Overcoming these barriers is essential for improving patient outcomes and reducing mortality rates.
By Product Insights: The reagents and consumables segment held the highest proportion. Over the course of the forecast period, the segment is also anticipated to increase at the fastest rate. Because screening products are easily accessible and frequently purchased by donors and recipients, the category is growing. Additionally, the market is driven by the extensive selection of donor screening, blood grouping, and typing reagents, kits, and assays provided by both domestic and international producers.
By Sample Type Insights: The blood culture category is anticipated to grow at the quickest rate over the forecast period. For the diagnosis of bacterial, fungal, and mycobacterial illnesses, among others, blood culture tests are crucial. Healthcare practitioners employ both computerized and manual techniques to identify these infections.
By Technology Insights: The PCR segment is anticipated to have the fastest compound annual growth rate (CAGR) during the projection period. The polymerase chain reaction (PCR) is the most popular nucleic acid amplification technique for directly detecting pathogens from blood and positive blood cultures. The PCR tests used in diagnostic labs are based on either multiplex PCR or broad-range PCR. Among the key drivers anticipated to propel the growth of the PCR market are the expanding number of forensic and research laboratories, the growing demand for sophisticated bloodstream infection testing techniques, and the rising incidence of infectious and chronic disorders.
By End Use Insights: The hospital and diagnostic centers category dominated the market. Bloodstream infections continue to be a major healthcare concern, and hospitals are at the forefront of diagnosing and treating them. Accurate and prompt bloodstream infection testing is becoming more and more important in order to inform the right treatment choices as hospital-acquired infections and sepsis cases increase. Hospitals' need for bloodstream infection testing services is fueled by this. Furthermore, hospitals and other healthcare institutions place a high priority on patient safety and infection control. Strong bloodstream infection testing procedures are put in place to assist detect infections early, stop them from spreading, and improve patient outcomes.
By Regional Insights: North America held the biggest revenue share and dominated the market. The region's highly established health infrastructure, advantageous reimbursement policies, rising disposable income, and an increase in strategic efforts and product releases by the key market players are all contributing factors. Magnolia Medical Technologies, Inc. and BD, a multinational medical technology firm, signed a business deal in October 2022. The partnership intends to help U.S. hospitals improve clinical outcomes by lowering blood culture contamination and increasing test accuracy. As a result, these programs that use efficient equipment and technologies improve the accuracy and dependability of blood culture testing, which increases the need for these testing techniques in the area.
Market Competitive Landscape
The market for Bloodstream Infection Testing is very competitive. Companies are focusing on product innovation, developing rapid and accurate diagnostic tests to meet the evolving needs of healthcare providers. Some of the prominent players in Global Bloodstream Infection Testing Market are Accelerate Diagnostics Inc., BD, bioMérieux SA, Bruker, Cepheid, F. Hoffmann-La Roche Ltd, Luminex Corporation, Seegene Inc., Siemens Healthcare Limited, T2 Biosystems Inc.
Recent Developments:
- In November 2024: The U.S. Food and Drug Administration (FDA) approved Prenosis' Sepsis Immunoscore, the first AI-based diagnostic tool for sepsis. This test employs an artificial intelligence algorithm to assess 22 health metrics, including vital signs and blood measurements, to generate a sepsis risk score. This score assists physicians in making informed decisions about initiating treatment, aiming to improve early detection and patient outcomes in sepsis management.
- In July 2022: T2 Biosystems, Inc., a well-known company that specializes in the early detection of sepsis-causing antibiotic resistance genes and bacteria, has received a grant from the United States Food and Drug Administration (FDA) for their T2Lyme panel. This panel enables physicians to guarantee that patients receive appropriate therapy as soon as possible, while also avoiding treatment-related side effects and antibiotic misuse.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Sample Type, By Technology, By End Use. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Accelerate Diagnostics Inc., BD, bioMérieux SA, Bruker, Cepheid, F. Hoffmann-La Roche Ltd, Luminex Corporation, Seegene Inc., Siemens Healthcare Limited, T2 Biosystems Inc. |
Key Topics Covered in the Report
- Global Bloodstream Infection Testing Market Size (FY'2025-FY'2034)
- Overview of Global Bloodstream Infection Testing Market
- Segmentation of Global Bloodstream Infection Testing Market By Product (Reagents & Consumables and Instruments)
- Segmentation of Global Bloodstream Infection Testing Market By Sample Type (Whole Blood and Blood Culture)
- Segmentation of Global Bloodstream Infection Testing Market By Technology (PCR, Mass Spectroscopy, In Situ Hybridization and Others)
- Segmentation of Global Bloodstream Infection Testing Market By End Use (Hospitals & Diagnostic Centers, Custom Laboratory Service Providers, Academic & Research Institutes and Others)
- Statistical Snap of Global Bloodstream Infection Testing Market
- Expansion Analysis of Global Bloodstream Infection Testing Market
- Problems and Obstacles in Global Bloodstream Infection Testing Market
- Competitive Landscape in the Global Bloodstream Infection Testing Market
- Details on Current Investment in Global Bloodstream Infection Testing Market
- Competitive Analysis of Global Bloodstream Infection Testing Market
- Prominent Players in the Global Bloodstream Infection Testing Market
- SWOT Analysis of Global Bloodstream Infection Testing Market
- Global Bloodstream Infection Testing Market Future Outlook and Projections (FY'2025-FY'2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Bloodstream Infection Testing Market Manufacturing Base Distribution, Sales Area, Interface Type6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Bloodstream Infection Testing Market
7. Global Bloodstream Infection Testing Market, By Product 2021-2034 (USD Million)
7.1. Reagents & Consumables7.2. Instruments
8. Global Bloodstream Infection Testing Market, By Sample Type 2021-2034 (USD Million)
8.1. Whole Blood8.2. Blood Culture
9. Global Bloodstream Infection Testing Market, By Technology 2021-2034 (USD Million)
9.1. PCR9.2. Mass Spectroscopy9.3. In Situ Hybridization9.4. Others
10. Global Bloodstream Infection Testing Market, By End Use 2021-2034 (USD Million)
10.1. Hospitals & Diagnostic Centers10.2. Custom Laboratory Service Providers10.3. Academic & Research Institutes10.4. Others
11. Global Bloodstream Infection Testing Market Forecast, 2021-2034 (USD Million)
11.1. Global Bloodstream Infection Testing Market Size and Market Share
12. Global Bloodstream Infection Testing Market, By Region, 2021-2034 (USD Million)
12.1. Asia-Pacific
12.1.1. Australia12.1.2. China12.1.3. India12.1.4. Japan12.1.5. South Korea12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France12.2.2. Germany12.2.3. Italy12.2.4. Spain12.2.5. United Kingdom12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia12.3.2. United Arab Emirates12.3.3. Qatar12.3.4. South Africa12.3.5. Egypt12.3.6. Morocco12.3.7. Nigeria12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada12.4.2. Mexico12.4.3. United States
12.5. Latin America
12.5.1. Argentina12.5.2. Brazil12.5.3. Rest of Latin America
13. Company Profile
13.1. Accelerate Diagnostics Inc.
13.1.1. Company details13.1.2. Financial outlook13.1.3. Interface summary13.1.4. Recent developments
13.2. BD
13.2.1. Company details13.2.2. Financial outlook13.2.3. Interface summary13.2.4. Recent developments
13.3. bioMérieux SA
13.3.1. Company details13.3.2. Financial outlook13.3.3. Interface summary13.3.4. Recent developments
13.4. Bruker
13.4.1. Company details13.4.2. Financial outlook13.4.3. Interface summary13.4.4. Recent developments
13.5. Cepheid
13.5.1. Company details13.5.2. Financial outlook13.5.3. Interface summary13.5.4. Recent developments
13.6. F. Hoffmann-La Roche Ltd.
13.6.1. Company details13.6.2. Financial outlook13.6.3. Interface summary13.6.4. Recent developments
13.7. Luminex Corporation
13.7.1. Company details13.7.2. Financial outlook13.7.3. Interface summary13.7.4. Recent developments
13.8. Seegene Inc.
13.8.1. Company details13.8.2. Financial outlook13.8.3. Interface summary13.8.4. Recent developments
13.9. Siemens Healthcare Limited
13.9.1. Company details13.9.2. Financial outlook13.9.3. Interface summary13.9.4. Recent developments
13.10. T2 Biosystems Inc.
13.10.1. Company details13.10.2. Financial outlook13.10.3. Interface summary13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The key players in the Market include Companies Covered Accelerate Diagnostics Inc., BD, bioMérieux SA, Bruker, Cepheid, F. Hoffmann-La Roche Ltd, Luminex Corporation, Seegene Inc., Siemens Healthcare Limited, T2 Biosystems Inc.
Bloodstream Infection Testing Market is projected to reach USD 1208.2 million by 2034, growing at a CAGR of 4.59% during the forecast period.
Bloodstream Infection Testing Market grew in Market size from 2025. The Market is expected to reach USD 1208.2 million by 2034, at a CAGR of 4.59% during the forecast period.
Bloodstream Infection Testing Market CAGR of 4.59% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Bloodstream Infection Testing Market size is USD 1208.2 million from 2025 to 2034.
Bloodstream Infection Testing Market is covered By Product, By Function, By Application, By End-User.
The North America is anticipated to have the highest Market share in the Bloodstream Infection Testing Market.
Bloodstream infection (BSI) testing is a critical diagnostic process used to detect bacterial, fungal, or viral pathogens in the blood, enabling timely treatment and reducing the risk of severe complications such as sepsis. The market for BSI testing is growing due to the rising incidence of hospital-acquired infections, increasing antibiotic resistance, and a growing elderly population prone to infections.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
